- Home
- FCBC vs ETNB Comparison
FCBC vs ETNB Comparison
Compare FCBC & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCBC
- ETNB
- Stock Information
- Founded
- FCBC 1874
- ETNB 2018
- Country
- FCBC United States
- ETNB United States
- Employees
- FCBC N/A
- ETNB N/A
- Industry
- FCBC Major Banks
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- FCBC Finance
- ETNB Health Care
- Exchange
- FCBC Nasdaq
- ETNB Nasdaq
- Market Cap
- FCBC 758.2M
- ETNB 773.7M
- IPO Year
- FCBC 1992
- ETNB 2019
- Fundamental
- Price
- FCBC $40.22
- ETNB $11.06
- Analyst Decision
- FCBC Hold
- ETNB Strong Buy
- Analyst Count
- FCBC 1
- ETNB 9
- Target Price
- FCBC $38.00
- ETNB $31.43
- AVG Volume (30 Days)
- FCBC 35.1K
- ETNB 3.9M
- Earning Date
- FCBC 01-28-2025
- ETNB 03-07-2025
- Dividend Yield
- FCBC 8.18%
- ETNB N/A
- EPS Growth
- FCBC 4.94
- ETNB N/A
- EPS
- FCBC 2.80
- ETNB N/A
- Revenue
- FCBC $162,261,000.00
- ETNB N/A
- Revenue This Year
- FCBC N/A
- ETNB N/A
- Revenue Next Year
- FCBC $1.86
- ETNB N/A
- P/E Ratio
- FCBC $14.36
- ETNB N/A
- Revenue Growth
- FCBC 3.25
- ETNB N/A
- 52 Week Low
- FCBC $31.00
- ETNB $5.99
- 52 Week High
- FCBC $49.02
- ETNB $16.63
- Technical
- Relative Strength Index (RSI)
- FCBC 37.35
- ETNB 63.82
- Support Level
- FCBC $43.61
- ETNB $10.43
- Resistance Level
- FCBC $45.28
- ETNB $11.31
- Average True Range (ATR)
- FCBC 1.07
- ETNB 0.65
- MACD
- FCBC -0.43
- ETNB -0.02
- Stochastic Oscillator
- FCBC 2.01
- ETNB 70.90
About FCBC First Community Bankshares Inc. (VA)
First Community Bankshares Inc is a financial holding company that provides commercial banking products and services. The company is engaged in providing demand deposit accounts, savings, and money market accounts, certificates of deposits; commercial, consumer, and real estate mortgage loans, and lines of credit; various credit card, debit card, and automated teller machine card services; corporate and personal trust services; investment management services and life, health, and property and casualty insurance products. The company's revenue is mainly derived from interest, fees, and commissions.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).